Global Radiation Toxicity Treatment Market
Global Radiation Toxicity Treatment Market

Radiation Toxicity Treatment Comprehensive Study by Type (Potassium Iodide (ThyroShield, Iosat), Prussian blue (Radiogardase), Diethylenetriamine pentaacetic acid (DTPA), Others), Application (Hospitals, Research & Academic Institutes), Disease Type (Bone Marrow Syndrome (Hematopoietic), Gastrointestinal Syndrome (GI), Cardiovascular (CV), Central Nervous System (CNS) Syndrome), Indications (Acute Radiation Syndrome (Bone Marrow Syndrome (Hematopoietic), Gastrointestinal Syndrome (GI), Cardiovascular (CV), Central Nervous System (CNS) Syndrome), Chronic Radiation Syndrome), Radiation Type (Ionizing Radiation (Alpha Radiation, Beta Radiation, Gamma Radiation), Non-Ionizing Radiation) Players and Region - Global Market Outlook to 2026

Radiation Toxicity Treatment Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Mar 2021 Edition 207 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Radiation Toxicity Treatment Market Scope?
Radiation toxicity hereby involves exposure to ionizing radiation, which is most common in the alpha, beta, gamma, delta, and theta wavelengths, thereby leading to damages at the chromosomal and cellular levels. Radiation toxicity is mainly caused by deliberate or accidental radiation exposure in nuclear power plants. As many countries invest in nuclear power, the number of nuclear power plants has increased, increasing the likelihood that people will be poisoned by radiation, leading to an increase in the market. The treatment goals for radiation toxicity are to prevent further radioactive contamination, treat life-threatening injuries such as burns and trauma; reduce symptoms, and relieve pain. Some treatments can reduce damage to internal organs from radioactive particles. A person who has absorbed a very large dose of radiation nearly has a very little chance of recovery. Depending on the severity of the disease, death can occur within two days or two weeks. People with fatal radiation toxicity are given medication for pain, nausea, vomiting, and diarrhea. You can also benefit from psychological or pastoral care.

The Radiation Toxicity Treatment market study is being classified by Type (Potassium Iodide (ThyroShield, Iosat), Prussian blue (Radiogardase), Diethylenetriamine pentaacetic acid (DTPA) and Others), by Application (Hospitals and Research & Academic Institutes) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that Players from United States will contribute to the maximum growth of Global Radiation Toxicity Treatment market throughout the predicted period.

Aeolus Pharmaceuticals (United States), Cantex Pharmaceuticals (United States), Gamida Cell Ltd. (Israel), Ology Bioservices (United States), Caladrius Biosciences (United States), Novartis AG (Switzerland), Cleveland BioLabs Inc. (United States), Smith & Nephew (United Kingdom), Amgen Inc. (United States) and Partner Therapeutics, Inc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Tonix Pharmaceuticals (United States) and Onconova Therapeutics Inc. (United States).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Radiation Toxicity Treatment market by Type, Application and Region.

On the basis of geography, the market of Radiation Toxicity Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).




Influencing Market Trend
  • Favorable Reimbursements and Government Policies for Cancer Treatments
  • The Increased Acceptance of Factors That Are Colony Stimulated

Market Drivers
  • The Rising Installations of Radiation Therapy Machines for Treating Different Cancer Types
  • Increase the Number of Patients Getting Diagnosed With Radiation Toxicity
  • A Rise in the Number of Nuclear Plants

Opportunities
  • Technological Advancements in the Field Of Biologics
  • Increasing Government Support for Research and Development

Restraints
  • High Cost of Treatment

Challenges
  • Shortage of Trained Professional and Accessibility of Treatment


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Providers of Radiation Toxicity Treatment, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research & Media features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.
Report Objectives / Segmentation Covered
By Type
  • Potassium Iodide (ThyroShield, Iosat)
  • Prussian blue (Radiogardase)
  • Diethylenetriamine pentaacetic acid (DTPA)
  • Others
By Application
  • Hospitals
  • Research & Academic Institutes
By Disease Type
  • Bone Marrow Syndrome (Hematopoietic)
  • Gastrointestinal Syndrome (GI)
  • Cardiovascular (CV)
  • Central Nervous System (CNS) Syndrome

By Indications
  • Acute Radiation Syndrome [Bone Marrow Syndrome (Hematopoietic), Gastrointestinal Syndrome (GI), Cardiovascular (CV), Central Nervous System (CNS) Syndrome]
  • Chronic Radiation Syndrome

By Radiation Type
  • Ionizing Radiation [Alpha Radiation, Beta Radiation, Gamma Radiation]
  • Non-Ionizing Radiation

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Rising Installations of Radiation Therapy Machines for Treating Different Cancer Types
      • 3.2.2. Increase the Number of Patients Getting Diagnosed With Radiation Toxicity
      • 3.2.3. A Rise in the Number of Nuclear Plants
    • 3.3. Market Challenges
      • 3.3.1. Shortage of Trained Professional and Accessibility of Treatment
    • 3.4. Market Trends
      • 3.4.1. Favorable Reimbursements and Government Policies for Cancer Treatments
      • 3.4.2. The Increased Acceptance of Factors That Are Colony Stimulated
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Radiation Toxicity Treatment, by Type, Application, Disease Type, Indications, Radiation Type and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Radiation Toxicity Treatment (Value)
      • 5.2.1. Global Radiation Toxicity Treatment by: Type (Value)
        • 5.2.1.1. Potassium Iodide (ThyroShield, Iosat)
        • 5.2.1.2. Prussian blue (Radiogardase)
        • 5.2.1.3. Diethylenetriamine pentaacetic acid (DTPA)
        • 5.2.1.4. Others
      • 5.2.2. Global Radiation Toxicity Treatment by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Research & Academic Institutes
      • 5.2.3. Global Radiation Toxicity Treatment by: Disease Type (Value)
        • 5.2.3.1. Bone Marrow Syndrome (Hematopoietic)
        • 5.2.3.2. Gastrointestinal Syndrome (GI)
        • 5.2.3.3. Cardiovascular (CV)
        • 5.2.3.4. Central Nervous System (CNS) Syndrome
      • 5.2.4. Global Radiation Toxicity Treatment by: Indications (Value)
        • 5.2.4.1. Acute Radiation Syndrome [Bone Marrow Syndrome (Hematopoietic), Gastrointestinal Syndrome (GI), Cardiovascular (CV), Central Nervous System (CNS) Syndrome]
        • 5.2.4.2. Chronic Radiation Syndrome
      • 5.2.5. Global Radiation Toxicity Treatment by: Radiation Type (Value)
        • 5.2.5.1. Ionizing Radiation [Alpha Radiation, Beta Radiation, Gamma Radiation]
        • 5.2.5.2. Non-Ionizing Radiation
      • 5.2.6. Global Radiation Toxicity Treatment Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Radiation Toxicity Treatment (Price)
      • 5.3.1. Global Radiation Toxicity Treatment by: Type (Price)
  • 6. Radiation Toxicity Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Aeolus Pharmaceuticals (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Cantex Pharmaceuticals (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Gamida Cell Ltd. (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Ology Bioservices (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Caladrius Biosciences (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Cleveland BioLabs Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Smith & Nephew (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Amgen Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Partner Therapeutics, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Radiation Toxicity Treatment Sale, by Type, Application, Disease Type, Indications, Radiation Type and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Radiation Toxicity Treatment (Value)
      • 7.2.1. Global Radiation Toxicity Treatment by: Type (Value)
        • 7.2.1.1. Potassium Iodide (ThyroShield, Iosat)
        • 7.2.1.2. Prussian blue (Radiogardase)
        • 7.2.1.3. Diethylenetriamine pentaacetic acid (DTPA)
        • 7.2.1.4. Others
      • 7.2.2. Global Radiation Toxicity Treatment by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Research & Academic Institutes
      • 7.2.3. Global Radiation Toxicity Treatment by: Disease Type (Value)
        • 7.2.3.1. Bone Marrow Syndrome (Hematopoietic)
        • 7.2.3.2. Gastrointestinal Syndrome (GI)
        • 7.2.3.3. Cardiovascular (CV)
        • 7.2.3.4. Central Nervous System (CNS) Syndrome
      • 7.2.4. Global Radiation Toxicity Treatment by: Indications (Value)
        • 7.2.4.1. Acute Radiation Syndrome [Bone Marrow Syndrome (Hematopoietic), Gastrointestinal Syndrome (GI), Cardiovascular (CV), Central Nervous System (CNS) Syndrome]
        • 7.2.4.2. Chronic Radiation Syndrome
      • 7.2.5. Global Radiation Toxicity Treatment by: Radiation Type (Value)
        • 7.2.5.1. Ionizing Radiation [Alpha Radiation, Beta Radiation, Gamma Radiation]
        • 7.2.5.2. Non-Ionizing Radiation
      • 7.2.6. Global Radiation Toxicity Treatment Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Radiation Toxicity Treatment (Price)
      • 7.3.1. Global Radiation Toxicity Treatment by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Radiation Toxicity Treatment: by Type(USD Million)
  • Table 2. Radiation Toxicity Treatment Potassium Iodide (ThyroShield, Iosat) , by Region USD Million (2015-2020)
  • Table 3. Radiation Toxicity Treatment Prussian blue (Radiogardase) , by Region USD Million (2015-2020)
  • Table 4. Radiation Toxicity Treatment Diethylenetriamine pentaacetic acid (DTPA) , by Region USD Million (2015-2020)
  • Table 5. Radiation Toxicity Treatment Others , by Region USD Million (2015-2020)
  • Table 6. Radiation Toxicity Treatment: by Application(USD Million)
  • Table 7. Radiation Toxicity Treatment Hospitals , by Region USD Million (2015-2020)
  • Table 8. Radiation Toxicity Treatment Research & Academic Institutes , by Region USD Million (2015-2020)
  • Table 9. Radiation Toxicity Treatment: by Disease Type(USD Million)
  • Table 10. Radiation Toxicity Treatment Bone Marrow Syndrome (Hematopoietic) , by Region USD Million (2015-2020)
  • Table 11. Radiation Toxicity Treatment Gastrointestinal Syndrome (GI) , by Region USD Million (2015-2020)
  • Table 12. Radiation Toxicity Treatment Cardiovascular (CV) , by Region USD Million (2015-2020)
  • Table 13. Radiation Toxicity Treatment Central Nervous System (CNS) Syndrome , by Region USD Million (2015-2020)
  • Table 14. Radiation Toxicity Treatment: by Indications(USD Million)
  • Table 15. Radiation Toxicity Treatment Acute Radiation Syndrome [Bone Marrow Syndrome (Hematopoietic), Gastrointestinal Syndrome (GI), Cardiovascular (CV), Central Nervous System (CNS) Syndrome] , by Region USD Million (2015-2020)
  • Table 16. Radiation Toxicity Treatment Chronic Radiation Syndrome , by Region USD Million (2015-2020)
  • Table 17. Radiation Toxicity Treatment: by Radiation Type(USD Million)
  • Table 18. Radiation Toxicity Treatment Ionizing Radiation [Alpha Radiation, Beta Radiation, Gamma Radiation] , by Region USD Million (2015-2020)
  • Table 19. Radiation Toxicity Treatment Non-Ionizing Radiation , by Region USD Million (2015-2020)
  • Table 20. South America Radiation Toxicity Treatment, by Country USD Million (2015-2020)
  • Table 21. South America Radiation Toxicity Treatment, by Type USD Million (2015-2020)
  • Table 22. South America Radiation Toxicity Treatment, by Application USD Million (2015-2020)
  • Table 23. South America Radiation Toxicity Treatment, by Disease Type USD Million (2015-2020)
  • Table 24. South America Radiation Toxicity Treatment, by Indications USD Million (2015-2020)
  • Table 25. South America Radiation Toxicity Treatment, by Radiation Type USD Million (2015-2020)
  • Table 26. Brazil Radiation Toxicity Treatment, by Type USD Million (2015-2020)
  • Table 27. Brazil Radiation Toxicity Treatment, by Application USD Million (2015-2020)
  • Table 28. Brazil Radiation Toxicity Treatment, by Disease Type USD Million (2015-2020)
  • Table 29. Brazil Radiation Toxicity Treatment, by Indications USD Million (2015-2020)
  • Table 30. Brazil Radiation Toxicity Treatment, by Radiation Type USD Million (2015-2020)
  • Table 31. Argentina Radiation Toxicity Treatment, by Type USD Million (2015-2020)
  • Table 32. Argentina Radiation Toxicity Treatment, by Application USD Million (2015-2020)
  • Table 33. Argentina Radiation Toxicity Treatment, by Disease Type USD Million (2015-2020)
  • Table 34. Argentina Radiation Toxicity Treatment, by Indications USD Million (2015-2020)
  • Table 35. Argentina Radiation Toxicity Treatment, by Radiation Type USD Million (2015-2020)
  • Table 36. Rest of South America Radiation Toxicity Treatment, by Type USD Million (2015-2020)
  • Table 37. Rest of South America Radiation Toxicity Treatment, by Application USD Million (2015-2020)
  • Table 38. Rest of South America Radiation Toxicity Treatment, by Disease Type USD Million (2015-2020)
  • Table 39. Rest of South America Radiation Toxicity Treatment, by Indications USD Million (2015-2020)
  • Table 40. Rest of South America Radiation Toxicity Treatment, by Radiation Type USD Million (2015-2020)
  • Table 41. Asia Pacific Radiation Toxicity Treatment, by Country USD Million (2015-2020)
  • Table 42. Asia Pacific Radiation Toxicity Treatment, by Type USD Million (2015-2020)
  • Table 43. Asia Pacific Radiation Toxicity Treatment, by Application USD Million (2015-2020)
  • Table 44. Asia Pacific Radiation Toxicity Treatment, by Disease Type USD Million (2015-2020)
  • Table 45. Asia Pacific Radiation Toxicity Treatment, by Indications USD Million (2015-2020)
  • Table 46. Asia Pacific Radiation Toxicity Treatment, by Radiation Type USD Million (2015-2020)
  • Table 47. China Radiation Toxicity Treatment, by Type USD Million (2015-2020)
  • Table 48. China Radiation Toxicity Treatment, by Application USD Million (2015-2020)
  • Table 49. China Radiation Toxicity Treatment, by Disease Type USD Million (2015-2020)
  • Table 50. China Radiation Toxicity Treatment, by Indications USD Million (2015-2020)
  • Table 51. China Radiation Toxicity Treatment, by Radiation Type USD Million (2015-2020)
  • Table 52. Japan Radiation Toxicity Treatment, by Type USD Million (2015-2020)
  • Table 53. Japan Radiation Toxicity Treatment, by Application USD Million (2015-2020)
  • Table 54. Japan Radiation Toxicity Treatment, by Disease Type USD Million (2015-2020)
  • Table 55. Japan Radiation Toxicity Treatment, by Indications USD Million (2015-2020)
  • Table 56. Japan Radiation Toxicity Treatment, by Radiation Type USD Million (2015-2020)
  • Table 57. India Radiation Toxicity Treatment, by Type USD Million (2015-2020)
  • Table 58. India Radiation Toxicity Treatment, by Application USD Million (2015-2020)
  • Table 59. India Radiation Toxicity Treatment, by Disease Type USD Million (2015-2020)
  • Table 60. India Radiation Toxicity Treatment, by Indications USD Million (2015-2020)
  • Table 61. India Radiation Toxicity Treatment, by Radiation Type USD Million (2015-2020)
  • Table 62. South Korea Radiation Toxicity Treatment, by Type USD Million (2015-2020)
  • Table 63. South Korea Radiation Toxicity Treatment, by Application USD Million (2015-2020)
  • Table 64. South Korea Radiation Toxicity Treatment, by Disease Type USD Million (2015-2020)
  • Table 65. South Korea Radiation Toxicity Treatment, by Indications USD Million (2015-2020)
  • Table 66. South Korea Radiation Toxicity Treatment, by Radiation Type USD Million (2015-2020)
  • Table 67. Taiwan Radiation Toxicity Treatment, by Type USD Million (2015-2020)
  • Table 68. Taiwan Radiation Toxicity Treatment, by Application USD Million (2015-2020)
  • Table 69. Taiwan Radiation Toxicity Treatment, by Disease Type USD Million (2015-2020)
  • Table 70. Taiwan Radiation Toxicity Treatment, by Indications USD Million (2015-2020)
  • Table 71. Taiwan Radiation Toxicity Treatment, by Radiation Type USD Million (2015-2020)
  • Table 72. Australia Radiation Toxicity Treatment, by Type USD Million (2015-2020)
  • Table 73. Australia Radiation Toxicity Treatment, by Application USD Million (2015-2020)
  • Table 74. Australia Radiation Toxicity Treatment, by Disease Type USD Million (2015-2020)
  • Table 75. Australia Radiation Toxicity Treatment, by Indications USD Million (2015-2020)
  • Table 76. Australia Radiation Toxicity Treatment, by Radiation Type USD Million (2015-2020)
  • Table 77. Rest of Asia-Pacific Radiation Toxicity Treatment, by Type USD Million (2015-2020)
  • Table 78. Rest of Asia-Pacific Radiation Toxicity Treatment, by Application USD Million (2015-2020)
  • Table 79. Rest of Asia-Pacific Radiation Toxicity Treatment, by Disease Type USD Million (2015-2020)
  • Table 80. Rest of Asia-Pacific Radiation Toxicity Treatment, by Indications USD Million (2015-2020)
  • Table 81. Rest of Asia-Pacific Radiation Toxicity Treatment, by Radiation Type USD Million (2015-2020)
  • Table 82. Europe Radiation Toxicity Treatment, by Country USD Million (2015-2020)
  • Table 83. Europe Radiation Toxicity Treatment, by Type USD Million (2015-2020)
  • Table 84. Europe Radiation Toxicity Treatment, by Application USD Million (2015-2020)
  • Table 85. Europe Radiation Toxicity Treatment, by Disease Type USD Million (2015-2020)
  • Table 86. Europe Radiation Toxicity Treatment, by Indications USD Million (2015-2020)
  • Table 87. Europe Radiation Toxicity Treatment, by Radiation Type USD Million (2015-2020)
  • Table 88. Germany Radiation Toxicity Treatment, by Type USD Million (2015-2020)
  • Table 89. Germany Radiation Toxicity Treatment, by Application USD Million (2015-2020)
  • Table 90. Germany Radiation Toxicity Treatment, by Disease Type USD Million (2015-2020)
  • Table 91. Germany Radiation Toxicity Treatment, by Indications USD Million (2015-2020)
  • Table 92. Germany Radiation Toxicity Treatment, by Radiation Type USD Million (2015-2020)
  • Table 93. France Radiation Toxicity Treatment, by Type USD Million (2015-2020)
  • Table 94. France Radiation Toxicity Treatment, by Application USD Million (2015-2020)
  • Table 95. France Radiation Toxicity Treatment, by Disease Type USD Million (2015-2020)
  • Table 96. France Radiation Toxicity Treatment, by Indications USD Million (2015-2020)
  • Table 97. France Radiation Toxicity Treatment, by Radiation Type USD Million (2015-2020)
  • Table 98. Italy Radiation Toxicity Treatment, by Type USD Million (2015-2020)
  • Table 99. Italy Radiation Toxicity Treatment, by Application USD Million (2015-2020)
  • Table 100. Italy Radiation Toxicity Treatment, by Disease Type USD Million (2015-2020)
  • Table 101. Italy Radiation Toxicity Treatment, by Indications USD Million (2015-2020)
  • Table 102. Italy Radiation Toxicity Treatment, by Radiation Type USD Million (2015-2020)
  • Table 103. United Kingdom Radiation Toxicity Treatment, by Type USD Million (2015-2020)
  • Table 104. United Kingdom Radiation Toxicity Treatment, by Application USD Million (2015-2020)
  • Table 105. United Kingdom Radiation Toxicity Treatment, by Disease Type USD Million (2015-2020)
  • Table 106. United Kingdom Radiation Toxicity Treatment, by Indications USD Million (2015-2020)
  • Table 107. United Kingdom Radiation Toxicity Treatment, by Radiation Type USD Million (2015-2020)
  • Table 108. Netherlands Radiation Toxicity Treatment, by Type USD Million (2015-2020)
  • Table 109. Netherlands Radiation Toxicity Treatment, by Application USD Million (2015-2020)
  • Table 110. Netherlands Radiation Toxicity Treatment, by Disease Type USD Million (2015-2020)
  • Table 111. Netherlands Radiation Toxicity Treatment, by Indications USD Million (2015-2020)
  • Table 112. Netherlands Radiation Toxicity Treatment, by Radiation Type USD Million (2015-2020)
  • Table 113. Rest of Europe Radiation Toxicity Treatment, by Type USD Million (2015-2020)
  • Table 114. Rest of Europe Radiation Toxicity Treatment, by Application USD Million (2015-2020)
  • Table 115. Rest of Europe Radiation Toxicity Treatment, by Disease Type USD Million (2015-2020)
  • Table 116. Rest of Europe Radiation Toxicity Treatment, by Indications USD Million (2015-2020)
  • Table 117. Rest of Europe Radiation Toxicity Treatment, by Radiation Type USD Million (2015-2020)
  • Table 118. MEA Radiation Toxicity Treatment, by Country USD Million (2015-2020)
  • Table 119. MEA Radiation Toxicity Treatment, by Type USD Million (2015-2020)
  • Table 120. MEA Radiation Toxicity Treatment, by Application USD Million (2015-2020)
  • Table 121. MEA Radiation Toxicity Treatment, by Disease Type USD Million (2015-2020)
  • Table 122. MEA Radiation Toxicity Treatment, by Indications USD Million (2015-2020)
  • Table 123. MEA Radiation Toxicity Treatment, by Radiation Type USD Million (2015-2020)
  • Table 124. Middle East Radiation Toxicity Treatment, by Type USD Million (2015-2020)
  • Table 125. Middle East Radiation Toxicity Treatment, by Application USD Million (2015-2020)
  • Table 126. Middle East Radiation Toxicity Treatment, by Disease Type USD Million (2015-2020)
  • Table 127. Middle East Radiation Toxicity Treatment, by Indications USD Million (2015-2020)
  • Table 128. Middle East Radiation Toxicity Treatment, by Radiation Type USD Million (2015-2020)
  • Table 129. Africa Radiation Toxicity Treatment, by Type USD Million (2015-2020)
  • Table 130. Africa Radiation Toxicity Treatment, by Application USD Million (2015-2020)
  • Table 131. Africa Radiation Toxicity Treatment, by Disease Type USD Million (2015-2020)
  • Table 132. Africa Radiation Toxicity Treatment, by Indications USD Million (2015-2020)
  • Table 133. Africa Radiation Toxicity Treatment, by Radiation Type USD Million (2015-2020)
  • Table 134. North America Radiation Toxicity Treatment, by Country USD Million (2015-2020)
  • Table 135. North America Radiation Toxicity Treatment, by Type USD Million (2015-2020)
  • Table 136. North America Radiation Toxicity Treatment, by Application USD Million (2015-2020)
  • Table 137. North America Radiation Toxicity Treatment, by Disease Type USD Million (2015-2020)
  • Table 138. North America Radiation Toxicity Treatment, by Indications USD Million (2015-2020)
  • Table 139. North America Radiation Toxicity Treatment, by Radiation Type USD Million (2015-2020)
  • Table 140. United States Radiation Toxicity Treatment, by Type USD Million (2015-2020)
  • Table 141. United States Radiation Toxicity Treatment, by Application USD Million (2015-2020)
  • Table 142. United States Radiation Toxicity Treatment, by Disease Type USD Million (2015-2020)
  • Table 143. United States Radiation Toxicity Treatment, by Indications USD Million (2015-2020)
  • Table 144. United States Radiation Toxicity Treatment, by Radiation Type USD Million (2015-2020)
  • Table 145. Canada Radiation Toxicity Treatment, by Type USD Million (2015-2020)
  • Table 146. Canada Radiation Toxicity Treatment, by Application USD Million (2015-2020)
  • Table 147. Canada Radiation Toxicity Treatment, by Disease Type USD Million (2015-2020)
  • Table 148. Canada Radiation Toxicity Treatment, by Indications USD Million (2015-2020)
  • Table 149. Canada Radiation Toxicity Treatment, by Radiation Type USD Million (2015-2020)
  • Table 150. Mexico Radiation Toxicity Treatment, by Type USD Million (2015-2020)
  • Table 151. Mexico Radiation Toxicity Treatment, by Application USD Million (2015-2020)
  • Table 152. Mexico Radiation Toxicity Treatment, by Disease Type USD Million (2015-2020)
  • Table 153. Mexico Radiation Toxicity Treatment, by Indications USD Million (2015-2020)
  • Table 154. Mexico Radiation Toxicity Treatment, by Radiation Type USD Million (2015-2020)
  • Table 155. Radiation Toxicity Treatment: by Type(USD/Units)
  • Table 156. Company Basic Information, Sales Area and Its Competitors
  • Table 157. Company Basic Information, Sales Area and Its Competitors
  • Table 158. Company Basic Information, Sales Area and Its Competitors
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Radiation Toxicity Treatment: by Type(USD Million)
  • Table 167. Radiation Toxicity Treatment Potassium Iodide (ThyroShield, Iosat) , by Region USD Million (2021-2026)
  • Table 168. Radiation Toxicity Treatment Prussian blue (Radiogardase) , by Region USD Million (2021-2026)
  • Table 169. Radiation Toxicity Treatment Diethylenetriamine pentaacetic acid (DTPA) , by Region USD Million (2021-2026)
  • Table 170. Radiation Toxicity Treatment Others , by Region USD Million (2021-2026)
  • Table 171. Radiation Toxicity Treatment: by Application(USD Million)
  • Table 172. Radiation Toxicity Treatment Hospitals , by Region USD Million (2021-2026)
  • Table 173. Radiation Toxicity Treatment Research & Academic Institutes , by Region USD Million (2021-2026)
  • Table 174. Radiation Toxicity Treatment: by Disease Type(USD Million)
  • Table 175. Radiation Toxicity Treatment Bone Marrow Syndrome (Hematopoietic) , by Region USD Million (2021-2026)
  • Table 176. Radiation Toxicity Treatment Gastrointestinal Syndrome (GI) , by Region USD Million (2021-2026)
  • Table 177. Radiation Toxicity Treatment Cardiovascular (CV) , by Region USD Million (2021-2026)
  • Table 178. Radiation Toxicity Treatment Central Nervous System (CNS) Syndrome , by Region USD Million (2021-2026)
  • Table 179. Radiation Toxicity Treatment: by Indications(USD Million)
  • Table 180. Radiation Toxicity Treatment Acute Radiation Syndrome [Bone Marrow Syndrome (Hematopoietic), Gastrointestinal Syndrome (GI), Cardiovascular (CV), Central Nervous System (CNS) Syndrome] , by Region USD Million (2021-2026)
  • Table 181. Radiation Toxicity Treatment Chronic Radiation Syndrome , by Region USD Million (2021-2026)
  • Table 182. Radiation Toxicity Treatment: by Radiation Type(USD Million)
  • Table 183. Radiation Toxicity Treatment Ionizing Radiation [Alpha Radiation, Beta Radiation, Gamma Radiation] , by Region USD Million (2021-2026)
  • Table 184. Radiation Toxicity Treatment Non-Ionizing Radiation , by Region USD Million (2021-2026)
  • Table 185. South America Radiation Toxicity Treatment, by Country USD Million (2021-2026)
  • Table 186. South America Radiation Toxicity Treatment, by Type USD Million (2021-2026)
  • Table 187. South America Radiation Toxicity Treatment, by Application USD Million (2021-2026)
  • Table 188. South America Radiation Toxicity Treatment, by Disease Type USD Million (2021-2026)
  • Table 189. South America Radiation Toxicity Treatment, by Indications USD Million (2021-2026)
  • Table 190. South America Radiation Toxicity Treatment, by Radiation Type USD Million (2021-2026)
  • Table 191. Brazil Radiation Toxicity Treatment, by Type USD Million (2021-2026)
  • Table 192. Brazil Radiation Toxicity Treatment, by Application USD Million (2021-2026)
  • Table 193. Brazil Radiation Toxicity Treatment, by Disease Type USD Million (2021-2026)
  • Table 194. Brazil Radiation Toxicity Treatment, by Indications USD Million (2021-2026)
  • Table 195. Brazil Radiation Toxicity Treatment, by Radiation Type USD Million (2021-2026)
  • Table 196. Argentina Radiation Toxicity Treatment, by Type USD Million (2021-2026)
  • Table 197. Argentina Radiation Toxicity Treatment, by Application USD Million (2021-2026)
  • Table 198. Argentina Radiation Toxicity Treatment, by Disease Type USD Million (2021-2026)
  • Table 199. Argentina Radiation Toxicity Treatment, by Indications USD Million (2021-2026)
  • Table 200. Argentina Radiation Toxicity Treatment, by Radiation Type USD Million (2021-2026)
  • Table 201. Rest of South America Radiation Toxicity Treatment, by Type USD Million (2021-2026)
  • Table 202. Rest of South America Radiation Toxicity Treatment, by Application USD Million (2021-2026)
  • Table 203. Rest of South America Radiation Toxicity Treatment, by Disease Type USD Million (2021-2026)
  • Table 204. Rest of South America Radiation Toxicity Treatment, by Indications USD Million (2021-2026)
  • Table 205. Rest of South America Radiation Toxicity Treatment, by Radiation Type USD Million (2021-2026)
  • Table 206. Asia Pacific Radiation Toxicity Treatment, by Country USD Million (2021-2026)
  • Table 207. Asia Pacific Radiation Toxicity Treatment, by Type USD Million (2021-2026)
  • Table 208. Asia Pacific Radiation Toxicity Treatment, by Application USD Million (2021-2026)
  • Table 209. Asia Pacific Radiation Toxicity Treatment, by Disease Type USD Million (2021-2026)
  • Table 210. Asia Pacific Radiation Toxicity Treatment, by Indications USD Million (2021-2026)
  • Table 211. Asia Pacific Radiation Toxicity Treatment, by Radiation Type USD Million (2021-2026)
  • Table 212. China Radiation Toxicity Treatment, by Type USD Million (2021-2026)
  • Table 213. China Radiation Toxicity Treatment, by Application USD Million (2021-2026)
  • Table 214. China Radiation Toxicity Treatment, by Disease Type USD Million (2021-2026)
  • Table 215. China Radiation Toxicity Treatment, by Indications USD Million (2021-2026)
  • Table 216. China Radiation Toxicity Treatment, by Radiation Type USD Million (2021-2026)
  • Table 217. Japan Radiation Toxicity Treatment, by Type USD Million (2021-2026)
  • Table 218. Japan Radiation Toxicity Treatment, by Application USD Million (2021-2026)
  • Table 219. Japan Radiation Toxicity Treatment, by Disease Type USD Million (2021-2026)
  • Table 220. Japan Radiation Toxicity Treatment, by Indications USD Million (2021-2026)
  • Table 221. Japan Radiation Toxicity Treatment, by Radiation Type USD Million (2021-2026)
  • Table 222. India Radiation Toxicity Treatment, by Type USD Million (2021-2026)
  • Table 223. India Radiation Toxicity Treatment, by Application USD Million (2021-2026)
  • Table 224. India Radiation Toxicity Treatment, by Disease Type USD Million (2021-2026)
  • Table 225. India Radiation Toxicity Treatment, by Indications USD Million (2021-2026)
  • Table 226. India Radiation Toxicity Treatment, by Radiation Type USD Million (2021-2026)
  • Table 227. South Korea Radiation Toxicity Treatment, by Type USD Million (2021-2026)
  • Table 228. South Korea Radiation Toxicity Treatment, by Application USD Million (2021-2026)
  • Table 229. South Korea Radiation Toxicity Treatment, by Disease Type USD Million (2021-2026)
  • Table 230. South Korea Radiation Toxicity Treatment, by Indications USD Million (2021-2026)
  • Table 231. South Korea Radiation Toxicity Treatment, by Radiation Type USD Million (2021-2026)
  • Table 232. Taiwan Radiation Toxicity Treatment, by Type USD Million (2021-2026)
  • Table 233. Taiwan Radiation Toxicity Treatment, by Application USD Million (2021-2026)
  • Table 234. Taiwan Radiation Toxicity Treatment, by Disease Type USD Million (2021-2026)
  • Table 235. Taiwan Radiation Toxicity Treatment, by Indications USD Million (2021-2026)
  • Table 236. Taiwan Radiation Toxicity Treatment, by Radiation Type USD Million (2021-2026)
  • Table 237. Australia Radiation Toxicity Treatment, by Type USD Million (2021-2026)
  • Table 238. Australia Radiation Toxicity Treatment, by Application USD Million (2021-2026)
  • Table 239. Australia Radiation Toxicity Treatment, by Disease Type USD Million (2021-2026)
  • Table 240. Australia Radiation Toxicity Treatment, by Indications USD Million (2021-2026)
  • Table 241. Australia Radiation Toxicity Treatment, by Radiation Type USD Million (2021-2026)
  • Table 242. Rest of Asia-Pacific Radiation Toxicity Treatment, by Type USD Million (2021-2026)
  • Table 243. Rest of Asia-Pacific Radiation Toxicity Treatment, by Application USD Million (2021-2026)
  • Table 244. Rest of Asia-Pacific Radiation Toxicity Treatment, by Disease Type USD Million (2021-2026)
  • Table 245. Rest of Asia-Pacific Radiation Toxicity Treatment, by Indications USD Million (2021-2026)
  • Table 246. Rest of Asia-Pacific Radiation Toxicity Treatment, by Radiation Type USD Million (2021-2026)
  • Table 247. Europe Radiation Toxicity Treatment, by Country USD Million (2021-2026)
  • Table 248. Europe Radiation Toxicity Treatment, by Type USD Million (2021-2026)
  • Table 249. Europe Radiation Toxicity Treatment, by Application USD Million (2021-2026)
  • Table 250. Europe Radiation Toxicity Treatment, by Disease Type USD Million (2021-2026)
  • Table 251. Europe Radiation Toxicity Treatment, by Indications USD Million (2021-2026)
  • Table 252. Europe Radiation Toxicity Treatment, by Radiation Type USD Million (2021-2026)
  • Table 253. Germany Radiation Toxicity Treatment, by Type USD Million (2021-2026)
  • Table 254. Germany Radiation Toxicity Treatment, by Application USD Million (2021-2026)
  • Table 255. Germany Radiation Toxicity Treatment, by Disease Type USD Million (2021-2026)
  • Table 256. Germany Radiation Toxicity Treatment, by Indications USD Million (2021-2026)
  • Table 257. Germany Radiation Toxicity Treatment, by Radiation Type USD Million (2021-2026)
  • Table 258. France Radiation Toxicity Treatment, by Type USD Million (2021-2026)
  • Table 259. France Radiation Toxicity Treatment, by Application USD Million (2021-2026)
  • Table 260. France Radiation Toxicity Treatment, by Disease Type USD Million (2021-2026)
  • Table 261. France Radiation Toxicity Treatment, by Indications USD Million (2021-2026)
  • Table 262. France Radiation Toxicity Treatment, by Radiation Type USD Million (2021-2026)
  • Table 263. Italy Radiation Toxicity Treatment, by Type USD Million (2021-2026)
  • Table 264. Italy Radiation Toxicity Treatment, by Application USD Million (2021-2026)
  • Table 265. Italy Radiation Toxicity Treatment, by Disease Type USD Million (2021-2026)
  • Table 266. Italy Radiation Toxicity Treatment, by Indications USD Million (2021-2026)
  • Table 267. Italy Radiation Toxicity Treatment, by Radiation Type USD Million (2021-2026)
  • Table 268. United Kingdom Radiation Toxicity Treatment, by Type USD Million (2021-2026)
  • Table 269. United Kingdom Radiation Toxicity Treatment, by Application USD Million (2021-2026)
  • Table 270. United Kingdom Radiation Toxicity Treatment, by Disease Type USD Million (2021-2026)
  • Table 271. United Kingdom Radiation Toxicity Treatment, by Indications USD Million (2021-2026)
  • Table 272. United Kingdom Radiation Toxicity Treatment, by Radiation Type USD Million (2021-2026)
  • Table 273. Netherlands Radiation Toxicity Treatment, by Type USD Million (2021-2026)
  • Table 274. Netherlands Radiation Toxicity Treatment, by Application USD Million (2021-2026)
  • Table 275. Netherlands Radiation Toxicity Treatment, by Disease Type USD Million (2021-2026)
  • Table 276. Netherlands Radiation Toxicity Treatment, by Indications USD Million (2021-2026)
  • Table 277. Netherlands Radiation Toxicity Treatment, by Radiation Type USD Million (2021-2026)
  • Table 278. Rest of Europe Radiation Toxicity Treatment, by Type USD Million (2021-2026)
  • Table 279. Rest of Europe Radiation Toxicity Treatment, by Application USD Million (2021-2026)
  • Table 280. Rest of Europe Radiation Toxicity Treatment, by Disease Type USD Million (2021-2026)
  • Table 281. Rest of Europe Radiation Toxicity Treatment, by Indications USD Million (2021-2026)
  • Table 282. Rest of Europe Radiation Toxicity Treatment, by Radiation Type USD Million (2021-2026)
  • Table 283. MEA Radiation Toxicity Treatment, by Country USD Million (2021-2026)
  • Table 284. MEA Radiation Toxicity Treatment, by Type USD Million (2021-2026)
  • Table 285. MEA Radiation Toxicity Treatment, by Application USD Million (2021-2026)
  • Table 286. MEA Radiation Toxicity Treatment, by Disease Type USD Million (2021-2026)
  • Table 287. MEA Radiation Toxicity Treatment, by Indications USD Million (2021-2026)
  • Table 288. MEA Radiation Toxicity Treatment, by Radiation Type USD Million (2021-2026)
  • Table 289. Middle East Radiation Toxicity Treatment, by Type USD Million (2021-2026)
  • Table 290. Middle East Radiation Toxicity Treatment, by Application USD Million (2021-2026)
  • Table 291. Middle East Radiation Toxicity Treatment, by Disease Type USD Million (2021-2026)
  • Table 292. Middle East Radiation Toxicity Treatment, by Indications USD Million (2021-2026)
  • Table 293. Middle East Radiation Toxicity Treatment, by Radiation Type USD Million (2021-2026)
  • Table 294. Africa Radiation Toxicity Treatment, by Type USD Million (2021-2026)
  • Table 295. Africa Radiation Toxicity Treatment, by Application USD Million (2021-2026)
  • Table 296. Africa Radiation Toxicity Treatment, by Disease Type USD Million (2021-2026)
  • Table 297. Africa Radiation Toxicity Treatment, by Indications USD Million (2021-2026)
  • Table 298. Africa Radiation Toxicity Treatment, by Radiation Type USD Million (2021-2026)
  • Table 299. North America Radiation Toxicity Treatment, by Country USD Million (2021-2026)
  • Table 300. North America Radiation Toxicity Treatment, by Type USD Million (2021-2026)
  • Table 301. North America Radiation Toxicity Treatment, by Application USD Million (2021-2026)
  • Table 302. North America Radiation Toxicity Treatment, by Disease Type USD Million (2021-2026)
  • Table 303. North America Radiation Toxicity Treatment, by Indications USD Million (2021-2026)
  • Table 304. North America Radiation Toxicity Treatment, by Radiation Type USD Million (2021-2026)
  • Table 305. United States Radiation Toxicity Treatment, by Type USD Million (2021-2026)
  • Table 306. United States Radiation Toxicity Treatment, by Application USD Million (2021-2026)
  • Table 307. United States Radiation Toxicity Treatment, by Disease Type USD Million (2021-2026)
  • Table 308. United States Radiation Toxicity Treatment, by Indications USD Million (2021-2026)
  • Table 309. United States Radiation Toxicity Treatment, by Radiation Type USD Million (2021-2026)
  • Table 310. Canada Radiation Toxicity Treatment, by Type USD Million (2021-2026)
  • Table 311. Canada Radiation Toxicity Treatment, by Application USD Million (2021-2026)
  • Table 312. Canada Radiation Toxicity Treatment, by Disease Type USD Million (2021-2026)
  • Table 313. Canada Radiation Toxicity Treatment, by Indications USD Million (2021-2026)
  • Table 314. Canada Radiation Toxicity Treatment, by Radiation Type USD Million (2021-2026)
  • Table 315. Mexico Radiation Toxicity Treatment, by Type USD Million (2021-2026)
  • Table 316. Mexico Radiation Toxicity Treatment, by Application USD Million (2021-2026)
  • Table 317. Mexico Radiation Toxicity Treatment, by Disease Type USD Million (2021-2026)
  • Table 318. Mexico Radiation Toxicity Treatment, by Indications USD Million (2021-2026)
  • Table 319. Mexico Radiation Toxicity Treatment, by Radiation Type USD Million (2021-2026)
  • Table 320. Radiation Toxicity Treatment: by Type(USD/Units)
  • Table 321. Research Programs/Design for This Report
  • Table 322. Key Data Information from Secondary Sources
  • Table 323. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Radiation Toxicity Treatment: by Type USD Million (2015-2020)
  • Figure 5. Global Radiation Toxicity Treatment: by Application USD Million (2015-2020)
  • Figure 6. Global Radiation Toxicity Treatment: by Disease Type USD Million (2015-2020)
  • Figure 7. Global Radiation Toxicity Treatment: by Indications USD Million (2015-2020)
  • Figure 8. Global Radiation Toxicity Treatment: by Radiation Type USD Million (2015-2020)
  • Figure 9. South America Radiation Toxicity Treatment Share (%), by Country
  • Figure 10. Asia Pacific Radiation Toxicity Treatment Share (%), by Country
  • Figure 11. Europe Radiation Toxicity Treatment Share (%), by Country
  • Figure 12. MEA Radiation Toxicity Treatment Share (%), by Country
  • Figure 13. North America Radiation Toxicity Treatment Share (%), by Country
  • Figure 14. Global Radiation Toxicity Treatment: by Type USD/Units (2015-2020)
  • Figure 15. Global Radiation Toxicity Treatment share by Players 2020 (%)
  • Figure 16. Global Radiation Toxicity Treatment share by Players (Top 3) 2020(%)
  • Figure 17. Global Radiation Toxicity Treatment share by Players (Top 5) 2020(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. Aeolus Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 20. Aeolus Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 21. Cantex Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 22. Cantex Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 23. Gamida Cell Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 24. Gamida Cell Ltd. (Israel) Revenue: by Geography 2020
  • Figure 25. Ology Bioservices (United States) Revenue, Net Income and Gross profit
  • Figure 26. Ology Bioservices (United States) Revenue: by Geography 2020
  • Figure 27. Caladrius Biosciences (United States) Revenue, Net Income and Gross profit
  • Figure 28. Caladrius Biosciences (United States) Revenue: by Geography 2020
  • Figure 29. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 31. Cleveland BioLabs Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Cleveland BioLabs Inc. (United States) Revenue: by Geography 2020
  • Figure 33. Smith & Nephew (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. Smith & Nephew (United Kingdom) Revenue: by Geography 2020
  • Figure 35. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Amgen Inc. (United States) Revenue: by Geography 2020
  • Figure 37. Partner Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Partner Therapeutics, Inc. (United States) Revenue: by Geography 2020
  • Figure 39. Global Radiation Toxicity Treatment: by Type USD Million (2021-2026)
  • Figure 40. Global Radiation Toxicity Treatment: by Application USD Million (2021-2026)
  • Figure 41. Global Radiation Toxicity Treatment: by Disease Type USD Million (2021-2026)
  • Figure 42. Global Radiation Toxicity Treatment: by Indications USD Million (2021-2026)
  • Figure 43. Global Radiation Toxicity Treatment: by Radiation Type USD Million (2021-2026)
  • Figure 44. South America Radiation Toxicity Treatment Share (%), by Country
  • Figure 45. Asia Pacific Radiation Toxicity Treatment Share (%), by Country
  • Figure 46. Europe Radiation Toxicity Treatment Share (%), by Country
  • Figure 47. MEA Radiation Toxicity Treatment Share (%), by Country
  • Figure 48. North America Radiation Toxicity Treatment Share (%), by Country
  • Figure 49. Global Radiation Toxicity Treatment: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • Aeolus Pharmaceuticals (United States)
  • Cantex Pharmaceuticals (United States)
  • Gamida Cell Ltd. (Israel)
  • Ology Bioservices (United States)
  • Caladrius Biosciences (United States)
  • Novartis AG (Switzerland)
  • Cleveland BioLabs Inc. (United States)
  • Smith & Nephew (United Kingdom)
  • Amgen Inc. (United States)
  • Partner Therapeutics, Inc. (United States)
Additional players considered in the study are as follows:
Tonix Pharmaceuticals (United States) , Onconova Therapeutics Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation